SHANGHAI, March 6, 2014 /PRNewswire/ -- The 4th NextGen Conference organized by CPhI (March 27-28, Crowne Plaza Fudan Shanghai, China) will provide a special Generics Consistency Evaluation session to summarize the evaluation work of 2013 and explore programs of 2014. CPhI will gather all the essential and global resources at this conference for further information and experience sharing. Speakers of this summit are from two fields of the pharmaceutical industry: Regulatory Updates and Technology & Market.
In the aspect of regulatory updates, former Vice President of National Institutes for Food and Drug Control, Shaohong Jin, will deliver a speech on the topic of "Opportunities and Challenges of Generics Consistency Evaluation". Sr. Director of Regulatory Affairs of Xian Janssen will focus on "How to Understand Generics Consistency Evaluation and How to Face up to the Challenges of It". Mufeng Xie, the associate Chief Pharmacist of Shanghai Institutes for Food and Drug Control, will discuss the latest progress and practices of Generics consistency evaluation.
In the aspect of technology and market, general Manager of NTC Pharma, Nicola Travierso, will give a speech on the Generics market outlook and future development forecast. Lily Han, the general manager of Tasly VC Investment and International Department will focus on "Coming from Behind through Strategic Cooperation and Investment in M&A".
What's more, the general Manager of Shanghai Seanpharma, Xueming Xu, will deliver a fabulous speech on analysis of low molecular heparin generic products. Shanghai Seanpharma Co., Ltd was founded in 2005 and has been dedicated to R&D of LMWH products ever since. After 7 years of endeavors, they have successfully set up a LMWH-related platform and developed LMWHs including Enoxaparin Sodium, Dalteparin Sodium and other LMWHs.
For a detailed agenda and speaker introductions for Nextgen China 2014, please click http://www.nextgen-china.com/Download.aspx?id=6&lang=en-us&source=news0305.
